Biomarkers Consortium

The study is part of the Biomarkers Consortium, and will include the collection of DNA samples for future genomics research into ASD.

NEW YORK (GenomeWeb) – Proteomics firm Caprion this week launched its CNS ProteoCarta panel for the study of central nervous system diseases.

Teams led by researchers at George Mason University have published a pair of studies exploring protein signaling in breast and colon cancer that could offer new insights into treatments for the diseases.

Technology developed by Lance Liotta and Emanuel Petricoin will be used to find and identify biomarkers for evaluating new investigational therapies for the neoadjuvant-drug study.

The I-SPY effort will conduct pharmacogenomics-focused clinical trials for breast cancer drugs using Agendia's tests.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.